151 related articles for article (PubMed ID: 18521973)
1. Kaletra lower-strength pediatric tablet approved in Europe.
AIDS Patient Care STDS; 2008 May; 22(5):437-8. PubMed ID: 18521973
[No Abstract] [Full Text] [Related]
2. Kaletra approved in Canada.
TreatmentUpdate; 2001; 12(11):1-2. PubMed ID: 11570069
[TBL] [Abstract][Full Text] [Related]
3. Once-daily dosing of lopinavir/ritonavir (Kaletra) receives FDA approval.
AIDS Patient Care STDS; 2010 Jun; 24(6):395. PubMed ID: 20575157
[No Abstract] [Full Text] [Related]
4. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
[TBL] [Abstract][Full Text] [Related]
5. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
[No Abstract] [Full Text] [Related]
6. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
[No Abstract] [Full Text] [Related]
7. Preliminary pharmacokinetic data on ABT-378 encouraging.
AIDS Patient Care STDS; 1998 Feb; 12(2):146. PubMed ID: 11361913
[No Abstract] [Full Text] [Related]
8. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
[TBL] [Abstract][Full Text] [Related]
9. Changes in Kaletra labelling.
AIDS Patient Care STDS; 2004 Mar; 18(3):181-2. PubMed ID: 15116435
[No Abstract] [Full Text] [Related]
10. Anti-HIV agents. Using only lopinavir/ritonavir (Kaletra).
TreatmentUpdate; 2008 Jan; 20(1):1-2. PubMed ID: 18320690
[No Abstract] [Full Text] [Related]
11. Kaletra OK'd by FDA.
James JS
Posit Living; 2000 Nov; 9(9):8, 13. PubMed ID: 12154764
[No Abstract] [Full Text] [Related]
12. Kaletra goes it alone.
Huff B
GMHC Treat Issues; 2003 Sep; 17(9):11. PubMed ID: 14672062
[No Abstract] [Full Text] [Related]
13. Aluvia tablet approved in 19 African countries.
AIDS Patient Care STDS; 2007 Aug; 21(8):604-5. PubMed ID: 17902244
[No Abstract] [Full Text] [Related]
14. Lower dose of ritonavir approved for use with fosamprenavir.
Sax PE
AIDS Clin Care; 2007 Dec; 19(12):106. PubMed ID: 18399004
[No Abstract] [Full Text] [Related]
15. Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).
Chachad S; Gogtay J; Malhotra G; Purandare S
J Pharm Sci; 2010 Feb; 99(2):572-3; author reply 574. PubMed ID: 19718766
[No Abstract] [Full Text] [Related]
16. Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.
Rackley RJ
J Pharm Sci; 2010 Feb; 99(2):568-71; author reply 574. PubMed ID: 19746411
[No Abstract] [Full Text] [Related]
17. FDA notifications. FDA approves new dosing for Kaletra.
AIDS Alert; 2010 Jun; 25(6):70-1. PubMed ID: 20623833
[No Abstract] [Full Text] [Related]
18. Ugandan children receive lower-strength Aluvia.
AIDS Patient Care STDS; 2008 Jan; 22(1):86-7. PubMed ID: 18453040
[No Abstract] [Full Text] [Related]
19. Drug interactions. Kaletra and ezetimibe.
TreatmentUpdate; 2006; 18(3):8. PubMed ID: 17209242
[No Abstract] [Full Text] [Related]
20. Protease inhibitor combination.
AIDS Patient Care STDS; 1996 Feb; 10(1):50. PubMed ID: 11361664
[No Abstract] [Full Text] [Related]
[Next] [New Search]
